insulin-like growth factor I

Phase 1Small molecule

insulin-like growth factor I is one of 65 small molecule programs targeting Insulin resistance. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

HyperinsulinismActive, not recruiting

TendinopathyActive, not recruiting

Insulin ResistancePreclinical

Active, not recruiting

HyperinsulinismPreclinical

Active, not recruiting

TendinopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Edarbi

Takeda

Phase 3

1 2

Jardiance

Boehringer Ingelheim

Phase 3

2 3

Januvia

ZZydus Therapeutics Inc.

Phase 3

2 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 5

Parlodel

VVeroScience

Phase 3

1 6

Glucophage

Boehringer Ingelheim

Phase 3

1 7

Myrbetriq

Astellas

Phase 2

1 8

Metformin Hcl

Boehringer Ingelheim

Phase 3

2 9

Renagel

GGenzyme, a Sanofi Company

Phase 2

2 10

Avandia

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperinsulinism2 trials

Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Completed·—·N/A·NCT00004699·8 enrolled

Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Completed·—·Phase 2·NCT00004700·16 enrolled

Tendinopathy1 trial

Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-I

Unknown status·—·Phase 1·NCT01834989·40 enrolled

Insulin resistance1 trial

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

Completed·—·N/A·NCT00004419·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for insulin-like growth factor I. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — insulin-like growth factor I compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for insulin-like growth factor I. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's Hospital of Philadelphia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CChildren's Hospital of Philadelphia

insulin-like growth factor I

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperinsulinism2 trials

Tendinopathy1 trial

Insulin resistance1 trial

References

Drug Info

Quick Facts

Related News